Tauro 6-ethlchenodeoxycholic acid-d5 (sodium)

Tauro 6-ethlchenodeoxycholic acid-d5 sodium is deuterium labeled Tauro-obeticholic acid (HY-135399) . Tauro-obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an orally bioavailable farnesoid-X receptor (FXR) agonist[1].

Product Specifications

UNSPSC

12352211

Target

FXR; Isotope-Labeled Compounds

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

OC1CC[C@]2([C@@]([H])(C1)[C@H]([C@H]([C@@]3([C@@]2(CC[C@]4([C@]3(CC[C@@]4([C@H](C)CCC(NCCS(=O)(O[Na])=O)=O)[H])[H])C)[H])[H])O)C([2H])(C([2H])([2H])[2H])[2H])C

Molecular Formula

C28H43D5NNaO6S

Molecular Weight

554.77

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Markham A, et al. Obeticholic Acid: First Global Approval. Drugs. 2016 Aug;76 (12) :1221-6.